Ann: Update on Fast Track of Phase I Clinical Trials, page-2

Highlights:

• Bod has engaged with significant counterparties, Linnea, iX Biopharma and ex head of clinical trials for Sirtex Medical in developing its clinical trial program

• Extensive literature review completed – ‘trial ready’ deliverable method underway with formulation and dosages determined

• Significant reduction in estimated study timeframe reduced from 10 months to 3 months • Improved Phase I study design to provide more data with lower costs

• Trial designed assesses the safety, tolerability and pharmacokinetics of Bod’s unique cannabis extract and sublingual wafer delivery method

• Trials set to commence first half 2018